4-(4-硝基苯甲氧基)苯甲醛 | 67565-48-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(4-硝基苯甲氧基)苯甲醛
• 中文别名: 4-(4-硝基苄氧基)苯甲醛
• 英文名称: 4-((4-nitrobenzyl)oxy)benzaldehyde
• 英文别名: 4-(4-Nitrobenzyloxy)benzaldehyde；4-[(4-nitrophenyl)methoxy]benzaldehyde
• CAS: 67565-48-4
• 化学式: C₁₄H₁₁NO₄
• mdl: MFCD00017041
• 分子量: 257.246
• InChiKey: RIYUFYPNHRLRON-UHFFFAOYSA-N

物化性质

• 熔点：
  133-134°C
• 沸点：
  456.6±25.0 °C(Predicted)
• 密度：
  1.301±0.06 g/cm3(Predicted)
• 稳定性/保质期：
  远离氧化物、强酸和强碱。

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.071
• 拓扑面积：
  72.1
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 安全说明：
  S22,S24/25
• 海关编码：
  2913000090

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 4-(4-Nitrobenzyloxy)benzaldehyde
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
CAS-No. : 67565-48-4
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Skin irritation (Category 2), H315
Serious eye damage (Category 1), H318
Specific target organ toxicity - single exposure (Category 3), H335
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xi Irritant R37/38, R41
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Danger
Hazard statement(s)
H315 Causes skin irritation.
H318 Causes serious eye damage.
H335 May cause respiratory irritation.
Precautionary statement(s)
P261 Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.
P280 Wear protective gloves/ eye protection/ face protection.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
Other hazards - none

---

SECTION 3: Composition/information on ingredients
Substances
Formula : C14H11NO4
Molecular Weight : 257,25 g/mol
CAS-No. : 67565-48-4
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
4-(4-Nitrobenzyloxy)benzaldehyde
Skin Irrit. 2; Eye Dam. 1; -
STOT SE 3; H315, H318,
H335
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
4-(4-Nitrobenzyloxy)benzaldehyde
Xi, R37/38 - R41 -
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx)
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end use(s)
A part from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face particle
respirator type N100 (US) or type P3 (EN 143) respirator cartridges as a backup to engineering
controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use
respirators and components tested and approved under appropriate government standards such
as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evapouration rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong acids and strong bases, Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
Respiratory or skin sensitisation
no data available
Germ cell mutagenicity
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
Specific target organ toxicity - single exposure
no data available
Inhalation - May cause respiratory irritation.
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
no data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed
professional waste disposal service to dispose of this material. Dissolve or mix the material with a
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment
For this product a chemical safety assessment was not carried out

---

SECTION 16: Other information
Full text of H-Statements referred to under sections 2 and 3.
Eye Dam. Serious eye damage
H315 Causes skin irritation.
H318 Causes serious eye damage.
H335 May cause respiratory irritation.
Skin Irrit. Skin irritation
STOT SE Specific target organ toxicity - single exposure
Full text of R-phrases referred to under sections 2 and 3
Xi Irritant
R37/38 Irritating to respiratory system and skin.
R41 Risk of serious damage to eyes.
Further information
Copyright 2013 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

反应信息

• 作为反应物：
  描述：

  4-(4-硝基苯甲氧基)苯甲醛 在 sodium tetrahydroborate 、 potassium carbonate 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 4-methyl-N-(1-(4-((4-nitrobenzyl)oxy)benzyl)-1,2,3,4-tetrahydroquinolin-8-yl)-4H-thieno[3,2-b]pyrrole-5-carboxamide
  参考文献：
  名称：

  基于四氢喹啉的可逆LSD1抑制剂的设计，合成和生物学评估

  摘要：

  在多种肿瘤细胞中高度表达的LSD1的靶向调节是一种有前途的癌症治疗策略。几种LSD1抑制剂目前正在临床评估中，并且大多数这些抑制剂是不可逆的。在这里，我们报告基于新型四氢喹啉可逆LSD1抑制剂的设计，合成和生化评估。在MAO-A / B上对LSD1具有选择性的化合物18s和18x在分子水平上 分别表现出优异的LSD1抑制作用，IC 50 = 55 nM和540 nM。经典的Lineweaver–Burk图显示复合18s可能以非竞争性方式可逆地结合LSD1酶。分子对接用于揭示化合物的潜在结合方式并解释结构-活性关系。此外，化合物的18s和18倍显著抑制增殖（IC 50  = 1.13  μ M和1.15  μ分别用M，）和诱导细胞凋亡在MGC-803细胞与LSD1的高表达。化合物18x显示出可接受的肝微粒体稳定性。同时，18X没有出现在10〜抑制的CYP  μ中号体外。值得注意的是，口服化合

  DOI：

  10.1016/j.ejmech.2020.112243
• 作为产物：
  描述：

  1-(氯甲基)-4-硝基苯 、 对羟基苯甲醛 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以53%的产率得到4-(4-硝基苯甲氧基)苯甲醛
  参考文献：
  名称：

  异恶唑5（4H）one衍生物作为PTP1B抑制剂表现出抗肥胖作用

  摘要：

  在开发治疗性目标酶的抑制剂中，大量的时间和精力致力于大量化合物的制备。为了开发一种有效的蛋白酪氨酸磷酸酶（PTP）1B抑制剂作为抗肥胖和/或抗糖尿病药，我们使用简化的程序构建了一个异恶唑酮化学库，该程序避免了繁琐的后处理和纯化步骤。10×7异恶唑酮衍生物是通过将两半目标化合物偶联而合成的。当在试管中混合并加热时，前体产生的反应产物为沉淀物。短暂洗涤后，产物纯度足以用于酶促实验。通过制备用于偶联反应的前体，可以使用本方案在一天之内制备10×7库化合物。检查由此获得的文库化合物对PTP1B的抑制活性。其中，复合C3是PTP1B的最有效的抑制剂，其IC 50为2.3μ中号。还对易肥胖的小鼠品系中的C3进行了体内研究。饮食诱导的肥胖（DIO）/糖尿病小鼠分为两组，每组喂养高脂饮食（HFD）或HFD + C3，持续4周。与喂食HFD的对照组相比，在喂食期的四个星期内，C3喂食的小鼠组的体重显着减少。

  DOI：

  10.1002/asia.201100154

文献信息

• [EN] NOVEL PROTEIN TYROSINE PHOSPHATASE - IB INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DE PROTÉINE TYROSINE PHOSPHATASE - IB
  申请人：LUPIN LTD

  公开号：WO2009109999A1

  公开（公告）日：2009-09-11

  The present invention relates to the novel compounds of the general formula (I), wherein the symbols are same as described in specification, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, to process and intermediates for the preparation of the above said compounds, having the utility of these compounds in medicine and to methods for their therapeutic use, and their use in the treatment of metabolic disorders.

  本发明涉及一般式（I）的新化合物，其中符号与规范中描述的相同，它们的药学上可接受的盐，含有它们的药物组合物，用于制备上述化合物的过程和中间体，这些化合物在医学上的用途，以及它们的治疗用途的方法，以及它们在治疗代谢紊乱中的应用。
• Isoxazol-5(4H)one Derivatives as PTP1B Inhibitors Showing an Anti-Obesity Effect
  作者：Bhooshan Kafle、Nilkanth G. Aher、Deegendra Khadka、Hwangseo Park、Hyeongjin Cho

  DOI：10.1002/asia.201100154

  日期：2011.8.1

  prepared in a day by using the present protocol. The library compounds thus obtained were examined for their inhibitory activities against PTP1B. Among them, compound C3 was the most potent inhibitor of PTP1B with an IC50 of 2.3 μM. The in vivo effect of C3 was also examined in an obesity‐prone mouse strain. Diet‐induced obese (DIO)/diabetic mice were divided into two groups and each group was fed a

  在开发治疗性目标酶的抑制剂中，大量的时间和精力致力于大量化合物的制备。为了开发一种有效的蛋白酪氨酸磷酸酶（PTP）1B抑制剂作为抗肥胖和/或抗糖尿病药，我们使用简化的程序构建了一个异恶唑酮化学库，该程序避免了繁琐的后处理和纯化步骤。10×7异恶唑酮衍生物是通过将两半目标化合物偶联而合成的。当在试管中混合并加热时，前体产生的反应产物为沉淀物。短暂洗涤后，产物纯度足以用于酶促实验。通过制备用于偶联反应的前体，可以使用本方案在一天之内制备10×7库化合物。检查由此获得的文库化合物对PTP1B的抑制活性。其中，复合C3是PTP1B的最有效的抑制剂，其IC 50为2.3μ中号。还对易肥胖的小鼠品系中的C3进行了体内研究。饮食诱导的肥胖（DIO）/糖尿病小鼠分为两组，每组喂养高脂饮食（HFD）或HFD + C3，持续4周。与喂食HFD的对照组相比，在喂食期的四个星期内，C3喂食的小鼠组的体重显着减少。
• A Cofactor‐Substrate‐Based Supramolecular Fluorescent Probe for the Ultrafast Detection of Nitroreductase under Hypoxic Conditions
  作者：Yang Jiao、Lei Zhang、Xu Gao、Wen Si、Chunying Duan

  DOI：10.1002/anie.201915040

  日期：2020.4.6

  monitoring. By encapsulating a fluorescent substrate, L-NO2 , within the NADH mimic-containing metal-organic capsule Zn-MPB, we developed a cofactor-substrate-based supramolecular luminescent probe for ultrafast detection of hypoxia-related enzymes in solution in vitro and in vivo. The host-guest structure fuses the coenzyme and substrate into one supramolecular probe to avoid control by NADH, switching

  鉴定低氧条件下癌细胞中酶的位置和表达水平对于早期癌症诊断和监测至关重要。通过将荧光底物L-NO2封装在含NADH模拟物的金属有机胶囊Zn-MPB中，我们开发了一种基于辅因子底物的超分子发光探针，用于在体内和体外超快速检测溶液中与缺氧相关的酶。 。宿主-客体结构将辅酶和底物融合为一个超分子探针，以避免受到NADH的控制，从而将硝基还原酶的催化过程从双底物机制转换为单底物机制。该探针通过改变底物催化过程来提高酶效率，并通过分子内途径以增强的活性来提高电子转移效率。
• 基于苯并吲哚的NTR-1响应型荧光探针、制备方法及用途
  申请人：东南大学

  公开号：CN112624960B

  公开（公告）日：2022-10-14

  本发明公开了基于苯并吲哚的NTR‑1响应型荧光探针、制备方法及用途，结构如下。先将对羟基苯甲醛与对硝基溴化苄反应合成以醚键连接的稳定中间体NFP‑1‑M，然后再将1‑乙基‑2‑甲基苯并[cd]吲哚‑1‑氯化物与中间体NFP‑1‑M缩合，生成探针NFP‑1。该探针可以用于衡量细胞缺氧程度，有助于肿瘤早期诊断等。
• [EN] SUBSTITUTED ISOXAZOLE AMIDE COMPOUNDS AS INHIBITORS OF STEAROYL-COA DESATURASE 1 (SCD1)<br/>[FR] COMPOSÉS D'AMIDE D'ISOXAZOLE SUBSTITUÉS EN TANT QU'INHIBITEURS DE STÉAROYL-COA DÉSATURASE 1 (SCD1)
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014086704A1

  公开（公告）日：2014-06-12

  The invention is concerned with a compound of formula (I) and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and using the compound of formula (I) as well as pharmaceutical compositions containing such compounds. The compound of formula (I) are SCD1 inhibitors and may be useful in treating cancer.

  该发明涉及一种具有化学式(I)及其药学上可接受的盐的化合物。此外，本发明涉及制造和使用化学式(I)化合物的方法，以及含有这种化合物的药物组合物。化学式(I)的化合物是SCD1抑制剂，可能在治疗癌症方面有用。